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Introduction
Cancer therapies consisting chemotherapy, surgery, and 
radiotherapy are available, but in many cases have limited 
efficacy.[1] An ideal anticancer drug should have high 
potency and specificity in killing cancer cells without 
significant or fatal toxicity on normal cells, which is almost 
nonexistent. A model useful in predicting which patients are 
at increased risk of developing severe or fatal toxicity from 
chemotherapy[2] is used at present in predicting chemotherapy 
toxicity.
Modern anti-cancer therapies show better response and 
survival, but the side-effects and poor quality-of-life, 
frequently leads to discontinuation, dose reduction, and 
emergence of drug resistance.
Research has focused on developing safer chemotherapies 
by (a) exploring the anticancer properties of newer compounds 
or (b) by assessing drugs used in other nonmalignant diseases. 
Many plant derivatives are known to be effective against a 
variety of diseases with broad antibiotic and antimalignant 
activity.
In this regard, the reports on potential anti-cancerous effects 
of artemisinins and other antimalarials are a new development 
in pharmaceutical research as evidenced by nearly 200 papers 
on this topic published in the last two decades. The following 
review includes a literature search in PubMed with the 
key words “antimalarials,” “anti-cancer effects,” “novel 
chemotherapy,” and “chloroquine and antitumor activity” for 
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Abstract
The anti‑malarial drug artemisinin has shown anticancer activity in vitro and animal 
experiments, but experience in human cancer is scarce. However, the ability of artemisinins 
to kill cancer cells through a variety of molecular mechanisms has been explored. A PubMed 
search of about 127 papers on anti‑cancer effects of antimalarials has revealed that this class 
of drug, including other antimalarials, have several biological characteristics that include 
anticancer properties. Experimental evidences suggest that artemisinin compounds may be 
a therapeutic alternative in highly aggressive cancers with rapid dissemination, without 
developing drug resistance. They also exhibit synergism with other anticancer drugs with 
no increased toxicity toward normal cells. It has been found that semisynthetic artemisinin 
derivatives have much higher antitumor activity than their monomeric counterparts via 
mechanisms like apoptosis, arrest of cell cycle at G0/G1, and oxidative stress. The exact 
mechanism of activation and molecular basis of these anticancer effects are not fully 
elucidated. Artemisinins seem to regulate key factors such as nuclear factor‑kappa B, 
survivin, NOXA, hypoxia‑inducible factor‑1α, and BMI‑1, involving multiple pathways 
that may affect drug response, drug interactions, drug resistance, and associated parameters 
upon normal cells. Newer synthetic artemisinins have been developed showing substantial 
antineoplastic activity, but there is still limited information regarding the mode of action 
of these synthetic compounds. In view of the emerging data, specific interactions with 
established chemotherapy need to be further investigated in different cancer cells and their 
phenotypes and validated further using different semisynthetic and synthetic artemisinin 
derivatives.
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the last two decades. About 127 articles (abstracts and PMC of 
reviews and experimental data) were examined out of which 
94 were finally included.
Artemisinins
Artemisinin is a naturally occurring antimalarial showing 
anticancer properties.[3,4] It has few side effects[5] and drug 
resistance, but tolerance can occur.[6] Artemisinin and its 
derivatives have shown a potent anti-neoplastic activity in 
both drug-sensitive and resistant cancer cell lines in several 
studies.[4,7,8] Artemisinin is a sesquiterpene lactone with a 
1,2,4-trioxane ring system, extracted from the Chinese herb 
qinghao. Low water/oil solubility, poor bioavailability, and 
a short half-life in vivo (~2.5h) are the pharmacological 
shortcomings of artemisinins.[9,10] Hence, three generations of 
artemisinin-like semisynthetic and fully synthetic endoperoxide 
compounds were developed to overcome these limitations. Two 
generations of such semisynthetic compounds-artesunate, 
arteeter, artemether, and artemisone have good efficacy and 
tolerability. Of these artesunate is the most commonly used 
antimalarial although the second-generation artemisinin. 
Artemisone shows better pharmacokinetic profiles including 
a longer half-life and lower toxicity.
Antimalarials are also used in conditions like SLE or rheumatoid 
arthritis. It is known that quinine, chloroquine, primaquine, and 
quinacrine blocks the uptake and amino acid incorporation 
in vivo but have little effect on cell-free protein synthesis. 
Hence, the basic action of these drugs is amino acid blockage 
for uptake by the target cells.[3] Recently, several other targets 
for anticancer effects of chloroquine/hydroxychloroquine, 
both in cultured cancer cell lines as well as on human tumors 
grafted into mice have been reviewed[11] and some suggest that 
chloroquine synergistically enhanced the effects of conventional 
chemotherapy through inducing apoptosis in addition to 
blocking the autophagic but enhanching their anti-angiogenic 
actions.[12] These molecular targets in cancer cells are not 
fully identified, but artemisinins may target mitochondria, 
endoplasmic reticulum (ER), and the lysosome.
Anti‑cancer activity of artemisinins: The different 
pathways
The artemisinins’ endoperoxide moiety is responsible for its 
anti-malarial and anti-cancer effects. The endoperoxide bond is 
probably activated by reduced heme or ferrous iron, leading to 
cytotoxic carbon-centered radicals which are strong alkylating 
agents.[13,14] But the absence of the endoperoxide moiety does 
not completely abolish the anticancer activity but significantly 
reduces cytotoxicity, suggesting that anticancer activity may 
involve alternative mechanisms as well.[15] Drug concentrations 
required to have an effect on cancer cells are usually higher 
than those to kill malaria parasites.
Iron and heme metabolism have a role in the anticancer activity of 
artemisinin. Iron, heme or heme-bound proteins are responsible 
for bioreductive activation of artemisinin.[16-18] It has been 
found that preloading of cancer cells with iron or iron-saturated 
holotransferrin (diferric transferrin) triggers artemisinin 
cytotoxicity,[19-22] with an increase in artemisinin activity up to 
100-fold in some cell lines.[23] Furthermore, artemisinins tagged 
with iron-carrying compounds show greater activity compared 
with that of artemisinin alone.[23-25] Recently, it was shown that 
chemical modulation using succinylacetone, a heme synthesis 
inhibitor, decreases dihydroartemisinin (DHA) cytotoxicity 
in human promyelocytic leukemia cells (HL-60),[22] which is 
consistent with previous studies which found that induction 
of heme oxidase followed by down-regulation of the heme 
synthesis genes may also inhibit cytotoxicity of artemisinin 
dimers in the same cancer line.[26] Similarly, treatment with 
desferroxamine (iron chelator), inactivates these compounds.[27]
Continued multiplication, growth, and survival of malignant 
cells require higher iron metabolism.[22] Cancer cells 
demonstrate an increase in transferrin receptors (TfR) that 
are responsible for uptake and regulation of intracellular iron 
levels. Expressions of TfR in cancer cells may vary according 
to cell lines. However, they differ substantially from normal 
cells resulting in a high selectivity index of artemisinin and 
its derivatives. For example, leukemia (CCRF-CEM) and 
astrocytoma (U373) cells express TfR in 95% and 43% of 
the cell population, whereas normal monocytes express 
only ~1%.[28,29] Blocking the TfR by pretreatment with specific 
monoclonal antibodies may abolish artemisinin activity.[29]
High oxidative stress is a common anti-neoplastic property 
of anticancer drugs.[30] Tumor cells are vulnerable to radical 
oxygen species (ROS) damage due to lower expression of 
antioxidant enzymes such as superoxide dismutase, catalase, 
and glutathione peroxidase compared to normal cells.[30,31] It 
is postulated that iron-activated artemisinin releases highly 
alkylating carbon-centered radicals and ROS.[22,32] ROS 
generation may contribute to the selective action of artemisinin 
on cancer cells by DNA damage, enhanced apoptosis, growth 
arrest and reducing angiogenesis. Several studies have also 
associated artemisinin cytotoxicity with blocking cytokines, 
inhibiting tumor invasion, migration, and metastasis.[31] The 
selectivity of artemisinin may also be enhanced by selective 
targeting of cancer biomarkers or overexpressed cancer genes 
and proteins which are not detectable in normal tissues.[32] 
Artesunate-treated cells demonstrated early oncosis-like 
microscopic changes at subcellular structures by activation 
of ROS generation, suggesting that ROS-mediated damage 
is initiated by some triggering event. Experiments in the 
HL-60 cell line have revealed that early and rapid generation 
of ROS is associated with artemisinin-induced apoptosis 
induction and cell damage.[33] A study has demonstrated that 
ROS generation in artesunate-treated HeLa cells precedes 
cytotoxicity implicating it as the trigger. The electron transfer 
chain (ETC) in the mitochondrion has also been found to play 
a role in the generation of ROS.[34] However, cytotoxicity still 
persists in HeLa cells devoid of ETC indicating that other 
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sources of ROS may be present in these cells.[21] Overall, 
multiple ROS-independent mechanism of cell damage may 
operate in artemisinin-induced necrosis.
The antineoplastic toxicity of artemisinins may also be 
modulated by other factors like calcium metabolism, ER 
stress[20,21] and the expression of the translationally controlled 
tumor protein (TCTP) a binding calcium protein, which 
also is a parasite target.[4] ER appears to be a plausible site 
for artemisinin action because in HepG2 cells a fluorescent 
derivative has been shown to preferentially accumulate there. 
Although the expression of the gene TCTP was initially 
correlated with cancer cell response to artemisinins, a definite 
role for TCTP in this anticancer effect needs confirmation.[35]
Studies of sarcoendoplasmic Calcium ATPase (SERCA) 
as artemisinin target in cancer has reported that increases 
calcium concentrations occurred as a result of SERCA 
inhibition following the treatment with artemisinin.[26,36] 
Conversely, studies on two artemisinin dimers have shown 
that ROS-mediated induced ER-stress after treatment was 
independent of SERCA inhibition.[24] Interestingly, the 
behavior of a highly potent artemisinin dimer and thapsigargin 
(an SERCA inhibitor), appears to be similar although mediated 
at different molecular levels.[26] Thapsigargin lacks the 
endoperoxide moiety and induces ROS. But, carboxylic acid 
dimers 8a and 9 of artemisinin are more efficacious orally as 
antimalarials in rodents than either artelinic acid or sodium 
artesunate, and are strongly inhibitory but not cytotoxic in 
several human cancer cell lines.[37]
It has been found that dimeric and trimeric artemisinin 
derivatives have much higher antitumor activity than their 
monomeric counterparts. In the last decade, an increased number 
of reports on artemisinin dimeric compounds have confirmed 
this. Further studies on four series of C-10 nonacetal dimers, 
prepared from key trioxane alcohol 10beta-(2-hydroxyethyl) 
deoxoartemisinin (9b) in vitro in HL60 cells show that both 
phosphate ester dimers (14a and 14b) are more efficacious 
than doxorubicin. Interestingly, phosphate ester monomers 
9c and 9d, active in the low nanomolar region against 
Plasmodium falciparum, are inactive as anticancer agents at 
higher millimolar dosage, thus emphasizing the importance 
of two trioxane units for high antimalignant activity, and the 
nature of the linker in dimers of this type plays an important 
role in imparting potent anticancer activity.[38]
Artemisinins also have pleiotropic effects. The sensitivity and 
resistance of tumor cells depend on the mRNA expression 
of angiogenesis-related genes suggesting artemisinins 
exert their antitumor effects at least partly by inhibiting 
tumor angiogenesis. This was validated in 6 out of 30 
angiogenesis related genes in one study by microarray data.[39] 
Artemisinins may also be chemopreventive in addition to being 
antiproliferative since many chemopreventive drugs have 
antiangiogenic features.
Anticancer activity of artemisinin has been demonstrated 
primarily in vitro and in animal models. In a study, testing 55 cell 
lines showed that artesunate showed inhibitory effects against 
leukemia, colon, melanoma, breast, ovarian, prostate, central 
nervous system, and renal cancer cells.[39] The semisynthetic 
derivative DHA showed remarkable antineoplastic activity 
against pancreatic, leukemic, osteosarcoma, and lung cancer 
cells.[40] Moreover, artemisone was superior to artemisinin 
and showed better synergism with other anti-cancer agents.[41]
Artemisinin has also been found to act either directly by 
causing DNA damage or indirectly by interfering with several 
signaling pathways involved in carcinogenesis. The indirect 
DNA damage seems to be commoner than direct damage. In 
pancreatic cells, artesunate caused DNA fragmentation and 
membrane damage. Low doses of artesunate were associated 
with oncosis-like cell death, whereas higher concentrations 
caused apoptosis. But, extent and type of such damage can 
depend on the phenotype and the origin of cell line, varying in 
time- and dose-dependent manner. Notably, higher sensitivity 
to artesunate was observed in rapidly growing cell lines 
compared to slow growing cancer cells.[40]
Alternatively, DHA, artesunate, and artemether may possibly 
modulate genes and proteins coordinating growth signals, 
apoptosis, proliferative capacity, angiogenesis, tissue 
invasion, and metastasis. Complex interactions through 
different pathways may enhance the anticancer effect of these 
endoperoxide drugs leading to growth control and cell death.
Cyclin-dependent kinases (CDK) are the proteins transmitting 
signals to complete the cell cycle in normal cells. Normal 
growth depends on the ability to translate signals for cell 
division and replication. Proliferation in cancer cells is the 
result of mutations inducing amplification of growth signals, 
dysregulation of checkpoints, loss of sensitivity to growth 
inhibitors and deregulation of apoptosis.[42] Artemisinin 
compounds have been shown to exert both cytostatic and 
cytotoxic action on cancer cells at all cell cycle phases, and 
arrest at G0/G1 to S transition is more commonly affected.
[7] 
Artemisinin and its semisynthetic derivatives can interrupt cell 
growth in cancer lines either by disrupting the cell cycle kinetics 
or by interfering with proliferation-interacting pathways. 
DHA and artesunate are very potent growth inhibitors with 
multiple studies showing DHA as the more potent anticancer 
artemisinin-like compound than the artesunate, arteeter, and 
artemether.[7,40,41] Recently, artemisone also has shown such 
effects in 7 cells lines including melanoma and breast cancer 
cells with all cell cycle phases being arrested simultaneously 
by cytostatic effect.[42] Arrest of the cell cycle at G2/M was 
also observed after DHA treatment in different malignancies 
such as osteosarcoma, pancreas, leukemia, and ovarian cancer 
cells,[43-45] while, artesunate interferes with G2 in osteosarcoma, 
ovarian, and other cell lines. The underlying mechanisms of 
such growth arrest are diverse:[46] (a) alterations in the expression 
and activity of regulatory enzymes of the cell cycle, such as 
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CDK2-4 and -6 and D type cyclins (G1-to-S-phase transition) 
or CDK1, and A-type cyclin (G2/M), (b) down-regulation of 
CDK transcription, inhibition of CDK promoters or increase 
of p21, p27, and CDK inhibitor and (c) down-regulation 
of interacting proteins targeting multiple pathways. These 
have been documented in pancreatic, pulmonary, prostate 
and bone cancers. One study has identified artesunate with 
topoisomerase II, an inhibitor which inhibits the growth by 
interaction through multiple pathways.[47] Hence, artemisinins 
may interfere with several pathways that are common to 
different cancers.
Apoptosis is a process is mediated by a balance between the 
proapoptotic Bax, and the antiapoptotic Bcl2 Bcl2 family genes 
and their effects on the mitochondria are important for cancer 
control. An increase in the Bax/Bcl2 ratio leads to release of 
cytochrome c followed by stepwise activation of caspases 
leading to cell death.[33,48] Artemisinin sensitivity depends upon 
the level of expression of antiapoptotic (Bcl2) and proapoptotic 
genes (Bax) in a cancer cell line.[49] Apoptosis is rapidly induced 
by artemisinin in many cancer cell lines where mitochondrial 
membrane damage plays a central role in this process of cell 
death. Treatment with DHA in leukemia cells induced apoptosis 
after 1 h. In general, the apoptotic effects of artemisinin have 
been attributed to activation of the intrinsic pathway. Many 
studies have revealed that artemisinin-like compounds induce 
apoptosis by modulating the Bax/Bcl2 ratio.[20,46,50-53] Validating 
these observations, DHA and artesunate caused cytochrome 
c release, Bax overexpression, increase in Bax/Bcl2 ratio 31, 
and activation of caspases 3 and 9 in osteosarcoma cells. DHA 
also activates caspase 8 and decreases the levels of CDC25B, 
cyclin B1, and nuclear factor-kappa B (NF-kB). In the same 
circumstances, artesunate exposure decreases survivin which 
has also been involved in the apoptotic DHA response in lung 
cancer cells.[33] Similar findings have been reported in hepatoma 
cancer lines treated with DHA, where DHA and artemisinin 
seem to have similar potency.[54]
Some studies describe alterations on molecules acting on 
the extrinsic apoptotic pathway.[49] DHA may increase the 
transcription of the cell death receptor 5 (DR5) promoter 
and induces DR5 in different prostate cancer lines. In a 
study, combination treatment with TRAIL (a DR5 ligand) 
significantly increased the DHA proapoptotic effect by up to 
35%.[55]
Artemisinins usually promote apoptosis rather than necrosis 
in most cases although both have been reported. Induction of 
apoptosis is a major advantage of artemisinins’ anti-malignancy 
action since there is no associated inflammation or cell damage 
due to necrosis. Artemisinin-induced necrosis is associated 
with low levels of ATP and defective apoptotic mechanisms.
Artemisinins in cancer metastasis
Distant metastasis is a process in which malignant cells invade 
and spread through the extracellular matrix, associated with high 
mortality and morbidity. Artemisinin has anti-invasive effect in 
highly aggressive and invasive cancers, that is correlated with 
altered expression of the matrix metalloproteinases (MMP) 
genes and their effects on αvβ3 integrins.[56] During metastasis, 
the cancer cell loses the of expression of E-cadherin, a 
calcium-binding transmembrane molecule involved in cell 
to cell adhesion. Several genes encoding extracellular matrix 
processing proteases, motility factors, and adhesion proteins 
also act at different steps during metastasis. Inhibition of 
metastasis is achieved by artemisinin by increasing cell-cell 
adhesion by enhancing E-cadherin activity and Cdc42 
activation. Artemisinin augments cell to cell adhesion by 
increasing E-cadherin activity and Cdc42 activation which 
inhibits metastasis.[57] It has been observed that some cancer 
cells can have specific proteins interacting in different 
pathways. For example, in non-small cell lung cancer and 
fibrosarcoma, DHA treatment induced low levels of MMP2, 
MMP7, or MMP9 driven by AP-1 and NF-kB modulation or 
inactivation[58] suggesting DHA affects different pathways. 
Animal investigations have shown that in lung cancer, lymph 
node metastasis and lymphangiogenesis were resisted by 
artemisinin-mediated inhibition of vascular endothelial growth 
factor C (VEGF-C).[59] Artesunate generally has been found to 
be more effective in less differentiated cell lines.
Angiogenesis, needed for metastatic cancer cell survival, 
occurs by proliferation of endothelial cells through induction 
of VEGF, fibroblast growth factor (FGF), its receptors, 
and cytokines.[60] It involves several mechanisms including 
hypoxia-driven activation of expression of hypoxia-inducible 
factor (HIF)-1α and the aryl hydrocarbon receptor nuclear 
translocator and is controlled by angiostatin, endostatin, 
thrombospondin, TIMPs, PAI-1, and others.[59,60] Artemisinins, 
artesunate, and other derivatives inhibit neovascularization by 
modulating gene expression of angiogenic factors,[39] through 
downregulating growth factors (VEGF, FGF), HIF-1α, new 
vessel mediator angiogenin (ANG), the cysteine-rich angiogenic 
inducer (CYR61), some metalloproteinases (MMP9, MMP11, 
and BMP1), and collagens along with upregulation of 
angiogenesis inhibitors.[39,61] This is supported by experimental 
studies in different systems, proposing other molecular 
interactions too. NF-kB is crucial in regulating these multiple 
processes playing a key role in the anticancer effects. It is 
activated by DNA damage and other sources of cell stress 
and it is a mediator of apoptosis resistance[62] in response to 
drug exposure and studies show that a cytokine called Scatter 
factor (a hepatocyte growth factor) mediated cell protection 
involves antiapoptotic signaling from its receptor (c-Met) 
to PI3 kinase → c‑Akt → p21‑activated kinase‑1 (Pak1) → 
NF-kB[63] Reduced levels of NF-kB have been previously 
associated with proliferation and metastasis inhibition 
suggesting that NF-kB regulation may be a key role in the 
multimodal action of DHA in this system.[64,65] In addition, 
DHA prevents angiogenesis by depleting the levels of the 
VEGF flt‑1 and KDR/flk‑1‑receptors. Similar effects were 
experimentally validated in lymphatic endothelial cells and 
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Lewis lung carcinoma.[66] In pancreatic cells (BxPc-3) and 
BalB/c nude mice, DHA induced inhibition of NF-kB DNA 
binding and down-regulation of angiogenic-related targets like 
MMP9, VEGF, COX2, and IL-8.
Artemisinins in drug resistant cancer cells
Many tumors develop drug resistance over time. A leading 
cause is a drug efflux generated by overexpression of 
membrane protein pumps resulting in ineffective/low 
drug concentrations.[67] Cytotoxicity of artemisinins has 
shown to be unaffected in otherwise resistant/multiresistant 
cancer cells. One study revealed that genes related with 
resistance to the established anticancer drugs such as MDR1 
P-glycoprotein (Pgp), MRP1, and BCRP had no impact on 
artemisinins effect, and confirmed later on that the antitumor 
activity of artemisinin remains intact when resistance to other 
agents is present.[40] Artemisinins are effective in doxorubicin, 
metrotexate, and hydroxyurea-resistant cancer lines without 
cross-resistance. Furthermore, artesunate proapoptotic effect is 
not affected in a doxorubicin-resistant leukemia cell line; rather 
it potentiates doxorubicin’s apoptotic effects.[8] In another 
study, intact anticancer potency of artesunate was found 
equally in chemoresistant and chemosensitive neuroblastoma 
cell lines and primary neuroblastoma cultures.[68] Here, 
sensitivity to artesunate was intact in vincristine, doxorubicin, 
cisplatin, topotecan, mephalan, and etoposide-resistant cells. 
Only one cell line showed low sensitivity to artesunate which 
was related to low ROS formation and high expression 
of glutathione cysteine ligase (GCL), where depletion of 
glutathione mediated by a GCL inhibitor improved artesunate 
sensitivity. Pgp or p53 attenuation did not affect the sensitivity 
to artesunate. DHA has shown better efficacy in cell lines such 
as cholangiocarcinoma and hepatocarcinoma compared to 
other drugs; moreover, upregulation of MDR1, MRP1-2, or 
MRP3 had no effect on its potency.[69]
Lack of cross-resistance between anticancer agents and 
artemisinins may depend on different mechanisms. Most of 
the conventional anticancer agents are nucleoside analogs, 
whereas artemisinin’s action is primarily mediated by an 
ROS-dependent mechanism. In leukemias and human small 
cell lung cancer, artemisinins show no significant inhibition 
toward Pgp or MRP1,[8] suggesting overexpression of protein 
pump may not affect artemisinin’s potency. In another 
system, however, artemisinin increases doxorubicin resistance 
by upregulating mdrp through a different mechanism.[70] 
Malignancy, especially hematological, can have a high 
potential to modulate their intrinsic systems leading to 
activation alternative rescue pathways which needs addition 
of multiple agents. Studies indicate convergence of diverse 
genetic signal pathways to a limited number of key downstream 
regulators of apoptosis. Convergence of pathways can be 
targeting these pathways is one way to address the problem 
of genetic heterogeneity in cancers like acute leukemia. This 
would imply treating multiple molecular aberrations with fewer 
drugs and enhanced therapeutic benefit.[71]
Artemisinins in Combination 
Chemotherapy for Cancer
In anti-cancer combination therapy, the antineoplastic action 
of artemisinin may add independent antitumor activity with 
no added side effects. The reason may be that diverse action 
of artemisinin in different pathways may improve overall 
synergism.[70]
A strategy to overcome multidrug resistance in cancer involves 
the use of a combination of the antineoplastic agent and a 
chemomodulator which inhibits resistance-causing proteins. 
The effects of antimalarial drugs on human recombinant 
glutathione S-transferase (GSTs) activity in searching 
for clinically effective inhibitors of these enzymes need 
investigations as they are reduced significantly by antimalarials 
and thereby can increase the efficacy of alkylating agents to 
overcome drug resistance.
It has been reported that resistant cancer cells become sensitive 
by adding artemisinin to the conventional treatment called 
“chemosensitization.” DHA and artesunate have exhibited 
the strongest chemosensitizing/synergistic effects.[8,72] while 
artemisinin showed only additive and antagonistic actions. 
DHA significantly improves the efficacy of gemcitabine in 
pancreatic cancer which commonly develops resistance. 
In vitro and in vivo analysis in pancreatic cells demonstrated a 
DHA-induced increase in 4 fold growth-inhibition and 2-fold 
apoptosis respectively, compared to gemcitabine alone.[65] A 
dual action of DHA in potentiating gemcitabine activity and the 
inhibiting resistance has been attributed to DHA inhibition of 
gemcitabine-induced NF-kB activation and subsequent action 
on its targets.[65] A similar effect has been shown in hepatoma 
cancer cells irrespective of their p53 status.[54] DHA improves 
tumor growth inhibition synergistically by 45% when in 
combination with gemcitabine, while artemisinin only induces 
additive effects.[69]
Similarly, greater antitumor activity was observed in animal 
models when DHA in combination with cyclophosphamide 
and cisplatin was used in lung cancer and temozolomide in 
glioma cells. DHA promotes apoptotic and necrotic activity 
of temozolomide through ROS generation.[73] Increased 
artesunate anticancer activity has been observed in different 
combination regimens. Significant synergism was achieved 
with artesunate and the immunomodulator drug, lenalidomide 
combination. These evidences suggest that DHA and 
artesunate can potentiate antitumor agents and counter tumor 
resistance. However, the benefits of such combination therapy 
need to be validated further because therapeutic effects are 
influenced by the mode of action of the drugs and multiple 
interactions in particular systems and schedules. Artemisinins 
also improve radiation therapies. DHA treatment inhibits the 
radiation-induced expression of GST with associated ROS 
generation in glioma cells, where combination treatment is 
more effective than radiation or DHA alone.[74] The adjuvant 
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effect of artemisinin in other cancer treatments including 
hyperbaric oxygen has also been reported.[75]
Resistance to Artemisinins
Artemisinin resistant malaria has been reported from the Greater 
Mekong sub‑region of the Asia Pacific (Cambodia, China, 
Lao People’s Democratic Republic, Myanmar, Thailand 
and Vietnam) and in sub-Saharan Africa, specifically 
Angola.[76] In addition, unstable tolerance has been reported 
in patients with therapeutic failure. However, these tolerant 
strains are unstable and develop after several years of 
continuous drug exposure.[77] The multiple modes of action of 
artemisinins at different carcinogenic pathways may explain 
this. Some cell lines have shown low or no response to 
artemisinin or its derivatives. Examples include breast cancer 
cells, gastric cancer, and metastatic nasopharyngeal cancer 
cell lines.[56] In breast cancer, artemisinin response may be 
modified by estrogen receptors (ERα and ERb) responsible 
for cell proliferation. A recent study found some levels of 
cross-resistance to artesunate and DHA in a cisplatin-resistant 
neuroblastoma cell line, which was partially overcome by 
L-buthionine-S, R-sulfoximine, an inhibitor of the antioxidant 
GLC.[68]
However, in vitro resistance has been reported in experimental 
studies. These studies indicate that upregulation of the 
tumor suppressor p16INK4A and the antioxidant protein, 
catalase, may induce artesunate resistance irrespective of p53 
status.[78] Further, MDA-MB-231 metastatic cells showed 
complete artesunate resistance, whereas a similar treatment 
in non-metastatic cell line MDA-MB-468 exhibited lesser 
resistance. Further investigation on the mechanism of 
artesunate resistance indicates that upregulation of NF-κB, 
AP-1, and NMP-1 overcome artesunate apoptotic and 
antimetastatic action, thus allowing tumor progression.[79] It is 
presently unclear, whether artesunate-induced resistance are 
permanent, if other semisynthetic endoperoxides may induce 
a similar effect and whether a combinational therapy may 
delay or reverse the effect on cell lines bearing this phenotype. 
Another issue to consider is whether cancer cells may develop 
DHA resistance after repeated administration thereby limiting 
its antitumor effects. But experiments in DHA-resistant Molt-4 
human lymphoblastoid cell line (RTN) showed no significant 
cross-resistance to two synthetic artemisinin compounds.[80]
Artemisinins Toxicity
Dose-dependent toxicity is a major problem of anticancer 
therapy that can be overcome by increasing its efficacy with 
lower toxic drug concentrations. In spite of a wide use of 
artemisinin derivatives, toxicity in humans is negligible. 
The toxicity of artemisinin-like compounds can occur with 
long-term use, but treatments up to one year have shown no 
adverse effects.[17] DHA is the most neurotoxic artemisinin 
derivative. This has been reported in animal studies in a 
dose‑ and time‑dependent manner (≥7 days).[81] Hence, 
rapid elimination of artemisinin in oral form is safer than 
slow-release/oil-based intramuscular formulations.[5] Clinical 
doses for malaria is 3 times higher than its anticancer activity.[40] 
Thus, artemisinin may have benefits as an anticancer agent, as 
it can be used in combination without increased side effects 
while efficacy and dose‑reduction of more toxic anticancer 
agents can be possible. Brainstem neurotoxic encephalopathy 
has been reported in animal studies usually associated with 
long-term high-dose treatments.[82] Fatal overdose, especially 
in children may occur.
Artemether and artesunate have been used with good 
tolerability and lack of significant side effects in a variety of 
cancers such as laryngeal squamous cell carcinoma, malignant 
skin cancer, pituitary macroadenoma and advanced non-small 
cell lung.[17,83,84] They showed a substantial reduction of tumor 
size, increased survival with a significant improvement in 
disease control and metastasis reduction, especially with 
combination chemotherapy.[17] No new artesunate-related side 
effects were reported.[85]
New semisynthetic and fully synthetic derivatives of 
artemisinins with antineoplastic action
Limitations of artemisinins are short half-life, limited 
availability, and solubility; but they can be partly overcome by 
potent compounds with enhanced pharmacological properties. 
Novel semisynthetic endoperoxide compounds with selective 
anti-cancer activity have been developed. It has been found 
that dimeric and trimeric artemisinin derivatives display much 
higher antitumor activity than their monomeric counterparts. 
There has been an emphasis on the nature and stereochemistry 
of the dimer linker which may influence anticancer activity. 
The linker itself is inactive. Showing IC50 ranging from 
0.014 to 6 μM, these compounds demonstrated 3–60 fold 
more anticancer toxicity according to the nature of the linker, 
and with lipophilicity or electrophilic substitutions[85] in 
different cancer lines. An increased anticancer activity seems 
to be conferred by the stereoisomery of the linker and an 
amide terminus.[86] Homodimers of artesunic acid also have 
nanomolar inhibitory values when tested in chemo-resistant 
and sensitive leukemia cells. Although these new semisynthetic 
artemisinins have shown promise, further research is needed.
The different stereochemistry of the ether linkage of the 5 
dimers of artemisinins and some of its derivatives influence their 
anticancer activity. As an example, DHA (with a non-symmetrical 
dimer called dimer-3) and dihydrodeoxyartemisinin (with the 
corresponding endoperoxide lacking dimer or dimer-5) as 
an endoperoxide moiety had a stronger cytotoxicity.[13] They 
showed potent antiangiogenic properties, chemical stability, 
and greater cytotoxicity than the artesunate. This emphasizes 
the importance of two trioxane units for high antiproliferative 
activity, and also that the nature of the linker in dimers of 
this type plays a crucial role in imparting potent anticancer 
activity.[87]
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Fully synthetic Artemisinins such as some trioxolanes 
and ozonides with improved pharmacokinetics are under 
clinical development[86] as artemisinins are potentially 
effective drugs with enhanced pharmacokinetics and targeted 
anticancer properties. A series of tetraoxacyclohexanes 
have been shown to exhibit anticancer properties. A triol 
substituted compound has displayed prominent antitumor 
action in vivo toward melanoma and ovarian cancer in low 
concentrations.[88] Other have synthesized compounds with 
dual action (antimalarial/anticancer effect). These deoxycholic 
acid and cholic acid derived mixed tetraoxanes are cytotoxic 
at very low concentrations and particularly effective against 
melanoma cancer.[89]
Artemisinins and genetics in cancers
Recent research has been focusing on the determination 
of the mechanism of bioactivation and molecular events 
underlying the artemisinin effects. mRNA expression profiles 
associated with tumor cell response to artesunate, arteether, 
and artemether have shown that 208 out of 464 genes (45%) 
correlating significantly with IC50 values of at least one 
artemisinin derivative.[90] These genes were from different 
classes like drug resistance genes, DNA damage and repair 
genes, apoptosis-regulating genes, proliferation-associated 
genes, oncogenes, tumor suppressor genes, and also cytokines. 
Two different gene clusters were identified. One contained 
predominately genes which correlated significantly to all 
three artemisinin derivatives. This overlapping set of genes 
indicates common molecular mechanisms of tumor inhibition 
by all three drugs in which genes affecting cellular proliferation 
may play a central role. The second cluster contained genes 
differentially associated with the response of artemisinin 
derivatives to cancer cells. The number of correlating 
drug resistance genes in this cluster increased in the order 
Artesunate < Arteether < Artemether, paralleled by similarly 
increasing IC50 values of these three drugs. At present, the 
precise molecular events involved in initial triggering of ROS 
production in cancer cells remain elusive. Other aspects like 
ROS-independent mechanisms, direct DNA damage, and the 
role of p53 status in genotoxicity need to be further studied.
Since immunological markers are also involved in tumor 
formation by their ability to induce chronic inflammatory 
response, evasion of tumor recognition, and induce tolerance,[91] 
whether artemisinin may affect in these events also remains 
to be determined. Recently, the anti‑inflammatory effects of 
artemisinins have been attributed to the inhibition of Toll-like 
receptors, Syk tyrosine kinase, phospholipase Cγ, PI3K/Akt, 
MAPK, STAT-1/3/5, NF-κB, Sp1 and Nrf2/ARE signaling 
pathways.[92]
The potential advantage of antimalarials over conventional 
chemotherapy is that they cause less toxicity, have good 
synergism with other anti-cancer agents and radiotherapy, 
easy to administer, cheap and easily available. Their targeted 
anti-cancer activity is a great advantage, as demonstrated in 
retinoblastoma cells;[93] along with their lesser potential for 
developing drug resistance, and have a chemo/radio-sensitizing 
property.[17,82,86] The normal cells are generally unaffected.
Although human trials are unavailable, a safety and efficacy 
study with artesunate was conducted by Rutteman et al.[94] 
in 23 dogs with non-resectable tumors for 7–385 days at a 
dosage of 651–1178 (median 922) mg/m2. No neurological 
or cardiac toxicity was observed. Seven dogs exhibited no 
adverse effects at all. Transient fever and hematological/
gastrointestinal toxicity occurred in 16 dogs. One dog died 
from pneumonia. Plasma artesunate and DHA levels fell 
below the limit of detection within 8–12 h after artesunate 
administration while levels after 2 h were close to 1 μM. 
Artesunate produced a long-lasting complete remission in 
one case of cancer and short-term stabilization of another 
seven cases.
Future efforts should concentrate on improving the selectivity 
of artemisinins by selectively targeting cancer biomarkers 
or overexpressed cancer genes and proteins which are not 
detectable in normal tissues in order to improve the toxicity 
profile of present day anti‑cancer therapy.
Conclusion
Widely used as antimalarials for long, this drug class has 
diverse biological properties including strong anticancer 
activity; but how the antitumor activity is exerted following 
artemisinin activation is still not well-understood but is 
associated with multiple mechanisms, including reactive 
oxygen species (ROS), oxidative DNA damage, sustained DNA 
double-strand breaks, and apoptosis. A better understanding 
of common mechanisms under similar conditions in different 
cell systems will greatly help developing targeted artemisinin 
derivatives. Their ability to kill cancer cells through multiple 
and heterogeneous molecular events is documented, although 
the exact molecular basis of artemisinin-induced cell damage 
is not fully known. Apart from NF-κB, survivin, NOXA, 
HIF-1α, and BMI-1, other molecules need investigation that 
may influence drug response, drug interactions, mechanisms of 
resistance, and associated effects in normal cells. Experimental 
evidences, mostly animal studies indicate that artemisinins and 
its derivatives may be a therapeutic alternative in the future, 
particularly in highly metastatic and aggressive cancers without 
developing drug resistance. Synthetic endoperoxides may act 
synergistically with other anticancer drugs without additional 
side effects. However, the benefits of artemisinins and DHA 
with specific and established chemotherapy in the clinical 
setting need to be further explored in different cancers by 
co-targeting multiple pathways to minimize shifting of cancer 
biomarkers and drug toxicity. Simultaneously, long-term 
therapy with artemisinins will require close monitoring. 
Artemisinin antagonistic reactions and resistance must be 
cautiously validated using different semisynthetic derivatives. 
DHA, artesunate, and artemether are the endoperoxides 
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currently licensed for therapeutic use. Overall, discovery of 
artemisinin compounds’ antitumor effect has opened new 
vistas and the need for further large scale studies in this regard 
including candidate genes and cancer biomarkers.
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